USPTO serial 79143473
THERAMETRICS
Reviewed by CopyMark Law Group
Reg. 4654777Status 404
- Filing date
- Status date
- Registration date
- Dec 16, 2014
- Examiner
- SNYDER, NELSON B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with THERAMETRICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Steven A. Abreu
Steven A. Abreu Sunstein LLP100 High StreetBoston, MA 02110UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of cardiovascular and respiratory diseases, pulmonary fibrosis, sarcoidosis, lung disease, viral diseases, and infectious diseases; chemical preparations for sanitary purposes for medicine; pharmaceutical products for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, scleroderma, lupus erythematosus associated pulmonary hypertension, congenital systemic-to-pulmonary shunts associated pulmonary hypertension, portal hypertension associated pulmonary hypertension, HIV infection associated pulmonary hypertension, drugs and toxins associated pulmonary hypertension, glycogen storage disease associated pulmonary hypertension, Gaucher disease associated pulmonary hypertension, hereditary hemorrhagic telangiectasia associated pulmonary hypertension, hemoglobinopathies associated pulmonary hypertension, myeloproliferative disorders associated pulmonary hypertension, pulmonary veno-occlusive disease associated pulmonary hypertension, pulmonary capillary hemangiomatosis associated pulmonary hypertension, persistent pulmonary hypertension of the newborn, left-sided atrial or ventricular heart disease associated pulmonary hypertension, left-sided valvular heart disease associated pulmonary hypertension, pulmonary hypertension associated with chronic obstructive pulmonary disease, pulmonary hypertension associated with interstitial lung diseases, pulmonary hypertension associated with sleep disordered-breathing, pulmonary hypertension associated with alveolar hypoventilation disorders, pulmonary hypertension associated with chronic exposure to high altitude, pulmonary hypertension associated with developmental abnormalities, pulmonary hypertension due to chronic thrombotic and embolic diseases, pulmonary embolism due to tumor, parasites, foreign material, pulmonary hypertension associated with in situ thrombosis, pulmonary hypertension associated with sarcoidosis, pulmonary hypertension associated with histiocytosis X, pulmonary hypertension associated with lymphangiomatosis, pulmonary hypertension associated with sickle-cell disease, Eisenmenger syndrome, chronic fatigue syndrome, bronchial asthma, rheumatoid arthritis, lupus, Goodpasture's syndrome, Wegener's granulomatosis, type 1 diabetes mellitus, Hashimoto's thyroiditis, Grave's disease, multiple sclerosis, Guillain-Barre syndrome, Addison's disease, acute disseminated encephalomyelitis, antiphospholipid antibody syndrome, aplastic anemia, myasthenia gravis, opsoclonus myoclonus syndrome, optic neuritis, Ord's thyroiditis, acute respiratory distress syndrome, acute lung injury, Hamman-Rich syndrome, idiopathic pulmonary fibrosis, bronchiolitis obliterans, hypersensitivity pneumonitis, lymphangiomyomatosis (LAM), usual interstitial pneumonia (UIP), Von Gierke syndrome, Osler-Weber-Rendu-Syndrome, small cell lung carcinoma, cystic fibrosis, tuberculosis, Hepatitis B virus infections, psoriasis, allergic dermatitis, scar keloids, pyogenic granulomas, blistering disease, Kaposi sarcoma in AIDS patients, systemic sclerosis, persistent hyperplastic vitreous syndrome, diabetic retinopathy, retinopathy of prematurity, choroidal neovascularization, inflammatory bowel disease, periodontal disease, ascites, peritoneal adhesions, endometriosis, uterine bleeding, ovarian cysts, ovarian hyperstimulation, osteomyelitis, osteophyte formation, HIV-induced bone marrow angiogenesis, early diabetic nephropathy, cancer and malignancies and their metastases in numerous organs, hemangiomas, vasculitis, Sjögren's disease, DiGeorge syndrome, hereditary haemorrhagic telangiectasia, cavernous hemangioma, cutaneous hemangioma, lymphatic malformations, transplant arteriopathy, vascular anastomoses, adipose tissue in obesity, chronic allograft rejections; chemical preparations intended for healing, health care or medical and veterinary purposes, namely, chemical preparations for treating inflammatory, cardiovascular and respiratory diseases, pulmonary fibrosis, sarcoidosis, lung disease, viral diseases, and infectious diseases; chemical reagents for medical or veterinary purposes; diagnostic preparations for medical purposes; radiological contrast substances for medical purposes; detergents for medical purposes; medicated mouth care and treatment preparations; medicated skin care preparations | SECTION 71 - CANCELLED | — |
| 042 | Scientific research to order; conducting of research and development in the medical, pharmaceutical, pharmacological, biochemical and/or medical technology fields for others; conducting to order clinical studies and tests, namely, conducting clinical trials for others; assessment to order of scientific projects, namely, conducting scientific feasibility studies; scientific research consulting in the nature of evaluation to order of clinical studies and experiments; providing technical advice relating to operation of computers; providing scientific cooperations in the nature of providing scientific information in the field of pharmaceutical research; conducting scientific research projects in the medical, pharmaceutical, pharmacological, biochemical, and/or medical technology fields for others; scientific analysis laboratories | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by THERAMetrics holding AG
- Other trademarks owned by THERAMetrics holding AG
- Other trademarks owned by THERAMetrics holding AG
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named THERAMETRICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 16, 2024 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Jun 16, 2024 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Aug 8, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 7, 2022 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jul 7, 2022 | INPC | INVALIDATION PROCESSED | — |
| Mar 2, 2022 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 2, 2021 | C71T | CANCELLED SECTION 71 | — |
| Feb 10, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 16, 2019 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 12, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 7, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 7, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 16, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Dec 16, 2014 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 30, 2014 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 30, 2014 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 10, 2014 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 27, 2014 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 22, 2014 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 21, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 20, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 20, 2014 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jul 3, 2014 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jul 3, 2014 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jul 3, 2014 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 10, 2014 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 10, 2014 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 5, 2014 | ALIE | ASSIGNED TO LIE | — |
| May 23, 2014 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 4, 2014 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 14, 2014 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 14, 2014 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 14, 2014 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 13, 2014 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 11, 2014 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 10, 2014 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 7, 2014 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 6, 2014 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |